We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.43% | 105.46 | 106.64 | 105.475 | 106.40 | 3,598,121 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Abbott Laboratories (ABT) said its Architect Stat High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration.
The technology helps detect heart attacks faster and more accurately than contemporary troponin tests, the company said.
Abbott's blood test, known as High Sensitive Troponin-I in Europe and Asia, has been used throughout hospitals internationally and researched in more than 200 studies for its role in identifying heart disease and cardiac events, Abbott said.
With this clearance, the blood test may be sold in the U.S. for use on Abbott's fully automated Architect analyzer.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 25, 2019 08:37 ET (12:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
